Tinea Capitis

Article

In this infant, microscopic examination of a potassium hydroxide preparation of scalp scrapings revealed Trichophyton tonsurans, which is the most common causative organism in North America.

FigureThis circular lesion on the scalp of a 3-week-old infant is tinea capitis-a rare disorder in a neonate. A 2003 epidemiological survey revealed a striking increase in tinea capitis among African American children. The study showed that the carrier rate for scalp fungus with cultures that are positive for dermatophytes was up to 13% among African American children in elementary school.

1

In this infant, microscopic examination of a potassium hydroxide preparation of scalp scrapings revealed Trichophyton tonsurans, which is the most common causative organism in North America.

Treatment of tinea capitis is variable. Most medications are not FDA-approved, and few published trials discuss treatment for very young children. Most experts use high-dose oral griseofulvin (20 to 25 mg/kg/d for 6 to 8 weeks) as first-line therapy, because lower dosages have been proved to have higher treatment failures. Several other equally effective therapies, such as terbinafine, itraconazole, and fluconazole (at 3 to 6 mg/kg/d for 2 to 4 weeks), have been used outside the United States and off-label; however, these treatments cost significantly more.2 There is one report of a 16-day-old infant who did well after treatment with topical bifonazole 1%.3 Selenium sulfide shampoo can be used as adjunctive therapy.

In this infant, treatment with griseofulvin (20 mg/d for 6 weeks) led to complete resolution of the lesion with no side effects.

References:

  • Ghannoum M, Isham N, Hajjeh R, et al. Tinea capitis in Cleveland: survey of elementary school students. J Am Acad Dermatol. 2003;48:189-193.

  • Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr Ann. 2005;34:191-200.

  • Mosseri R, Finkelstein Y, Garty BZ. Topical treatment of tinea capitis in a neonate. Cutis. 2002;69:88-90.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Russell Libby, MD, FAAP
Lawrence Eichenfield, MD
Wendy Ripple, MD
Wendy Ripple, MD
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
Related Content
© 2025 MJH Life Sciences

All rights reserved.